Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 161,21 € (+69.991,30 %). Medianen er 161,21 € (+69.991,30 %).
| Køb |
2 |
| Behold |
3 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Co-Diagnostics positioned to supply decentralized Ebola and TB diagnostics
The WHO's PHEIC for the Bundibugyo Ebola outbreak has shifted national stockpile priorities toward rapid, locally produced diagnostics, creating demand tailwinds. Co-Diagnostics is advancing BDBV-specific and pan‑Ebola PCR assays and leverages international joint ventures—notably CoSara in India and a Saudi facility—to enable in‑country manufacturing and deployment. CoSara may pursue a public listing and will commercialize a tuberculosis test in South Asia in Q3 2026, while the parent targets an FDA 510(k) submission for the Co-Dx PCR platform in the same quarter. Recent financing, a low float and a reverse split have driven volatility; successful regulatory clearances and early TB revenues are key de‑risking milestones for investors. » Mere på investing.com
Virksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 145,57 t | 5,32 % |
| Bruttofortjeneste | 105,87 t | 4,60 % |
| Nettoresultat | -5,51 mio. | 16,05 % |
| EBITDA | -5,19 mio. | 17,71 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,71 mio. € |
Antal aktier | 7,45 mio. |
Højeste/laveste i 52 uger | 12,13 € - 0,22 € |
| Udbytte | Nej |
Beta | 3,20 |
P/E (PE Ratio) | -0,01 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | 0,09 |
P/S (PS Ratio) | 2,65 |
Virksomhedsprofil
| Navn | Co-Diagnostics |
| CEO | Dwight Egan |
| Medarbejdere | 115 |
